基因导向性酶前体药物疗法 (GDEPT)为肿瘤生物治疗最引人注目的研究领域 ,是继手术、放疗和化疗等传统疗法之后 ,一种具有良好应用前景的肿瘤治疗新措施 ,主要包括HSV tk GCV系统疗法和CD 5 FC系统疗法。为克服传统GDEPT疗法的不足 ,目前多主张联合基因治疗肿瘤 ,有人还提出一种全新的GDEPT疗法。现综述近几年来GDEPT在肿瘤基因治疗中的研究进展。 Gene-directed enzymatic prodrug therapy (GDEPT) is the most attractive research field for tumor biological therapy. It is a new treatment strategy for tumors with promising application, including HSV, following traditional treatments such as surgery, radiotherapy and chemotherapy. Tk GCV system therapy and CD 5 FC system therapy. In order to overcome the shortcomings of traditional GDEPT therapy, multiple gene therapy tumors are currently advocated, and some people have also proposed a new GDEPT therapy. The progress of GDEPT in tumor gene therapy in recent years is reviewed.